-$0.13 EPS Expected for AxoGen, Inc. (NASDAQ:AXGN) This Quarter

Wall Street brokerages expect AxoGen, Inc. (NASDAQ:AXGNGet Rating) to post earnings per share (EPS) of ($0.13) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for AxoGen’s earnings. The lowest EPS estimate is ($0.15) and the highest is ($0.10). AxoGen posted earnings per share of ($0.09) in the same quarter last year, which indicates a negative year over year growth rate of 44.4%. The business is expected to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that AxoGen will report full-year earnings of ($0.52) per share for the current year, with EPS estimates ranging from ($0.64) to ($0.37). For the next financial year, analysts expect that the company will report earnings of ($0.13) per share, with EPS estimates ranging from ($0.53) to $0.27. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover AxoGen.

AxoGen (NASDAQ:AXGNGet Rating) last posted its quarterly earnings data on Wednesday, May 4th. The medical equipment provider reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.03). The firm had revenue of $31.01 million during the quarter, compared to analysts’ expectations of $30.40 million. AxoGen had a negative net margin of 24.98% and a negative return on equity of 26.64%. During the same quarter in the previous year, the company posted ($0.15) EPS.

Several analysts have issued reports on the company. Canaccord Genuity Group raised AxoGen from a “hold” rating to a “buy” rating and upped their target price for the stock from $10.00 to $15.00 in a research note on Monday, May 9th. Canaccord Genuity Group upgraded AxoGen from a “hold” rating to a “buy” rating and raised their target price for the company from $10.00 to $15.00 in a research note on Monday, May 9th. Finally, StockNews.com initiated coverage on AxoGen in a research report on Thursday, March 31st. They issued a “hold” rating on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, AxoGen presently has a consensus rating of “Buy” and a consensus target price of $19.25.

Shares of NASDAQ AXGN opened at $9.72 on Monday. AxoGen has a 52 week low of $6.87 and a 52 week high of $22.82. The company has a market cap of $408.06 million, a P/E ratio of -12.79 and a beta of 0.75. The company has a quick ratio of 4.14, a current ratio of 4.90 and a debt-to-equity ratio of 0.63. The business has a 50-day simple moving average of $8.27 and a two-hundred day simple moving average of $8.86.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Deutsche Bank AG lifted its holdings in shares of AxoGen by 3.9% in the 4th quarter. Deutsche Bank AG now owns 32,758 shares of the medical equipment provider’s stock worth $307,000 after acquiring an additional 1,218 shares during the last quarter. OLD National Bancorp IN boosted its position in shares of AxoGen by 7.3% during the first quarter. OLD National Bancorp IN now owns 19,131 shares of the medical equipment provider’s stock valued at $152,000 after buying an additional 1,306 shares during the period. M&T Bank Corp grew its stake in shares of AxoGen by 5.8% during the fourth quarter. M&T Bank Corp now owns 24,118 shares of the medical equipment provider’s stock valued at $226,000 after buying an additional 1,316 shares during the last quarter. Royal Bank of Canada raised its holdings in shares of AxoGen by 15.9% in the third quarter. Royal Bank of Canada now owns 11,198 shares of the medical equipment provider’s stock worth $176,000 after buying an additional 1,536 shares during the period. Finally, California State Teachers Retirement System lifted its stake in shares of AxoGen by 3.3% during the 4th quarter. California State Teachers Retirement System now owns 54,123 shares of the medical equipment provider’s stock worth $507,000 after acquiring an additional 1,716 shares during the last quarter. Institutional investors own 74.07% of the company’s stock.

AxoGen Company Profile (Get Rating)

AxoGen, Inc, together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Featured Articles

Get a free copy of the Zacks research report on AxoGen (AXGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.